tiprankstipranks
Neximmune downgraded to Market Perform from Outperform at Raymond James
The Fly

Neximmune downgraded to Market Perform from Outperform at Raymond James

Raymond James analyst Timur Ivannikov downgraded Neximmune to Market Perform from Outperform without a price target. The analyst cites the company’s strategic program re-alignment for the downgrade and says he needs to see additional data from the AIM INJ platform in order to get more constructive on the shares. NexImmune is pausing enrollment in adoptive cell therapy studies and seeking external partnerships for NEXI-001 and NEXI-003, Ivannikov tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NEXI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles